The cooperating mutation or "second hit" determines the immunologic visibility toward MYC-induced murine lymphomas
- PMID: 21878673
- DOI: 10.1182/blood-2010-10-313098
The cooperating mutation or "second hit" determines the immunologic visibility toward MYC-induced murine lymphomas
Abstract
In Eμ-myc transgenic animals lymphoma formation requires additional genetic alterations, which frequently comprise loss of p53 or overexpression of BCL-2. We describe that the nature of the "second hit" affects the ability of the immune system to contain lymphoma development. Tumors with disrupted p53 signaling killed the host more rapidly than BCL-2 overexpressing ones. Relaxing immunologic control, using Tyk2(-/-) mice or by Ab-mediated depletion of CD8(+) T or natural killer (NK) cells accelerated formation of BCL-2-overexpressing lymphomas but not of those lacking p53. Most strikingly, enforced expression of BCL-2 prolonged disease latency in the absence of p53, whereas blocking p53 function in BCL-2-overexpressing tumors failed to accelerate disease. This shows that blocking apoptosis in p53-deficient cells by enforcing BCL-2 expression can mitigate disease progression increasing the "immunologic visibility." In vitro cytotoxicity assays confirmed that high expression of BCL-2 protein facilitates NK and T cell-mediated killing. Moreover, we found that high BCL-2 expression is accompanied by significantly increased levels of the NKG2D ligand MULT1, which may account for the enhanced killing. Our findings provide first evidence that the nature of the second hit affects tumor immunosurveillance in c-MYC-driven lymphomas and define a potential shortcoming of antitumor therapies targeting BCL-2.
Similar articles
-
Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis.Genes Dev. 1999 Oct 15;13(20):2658-69. doi: 10.1101/gad.13.20.2658. Genes Dev. 1999. PMID: 10541552 Free PMC article.
-
Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53.Oncogene. 2016 Jul 21;35(29):3866-71. doi: 10.1038/onc.2015.457. Epub 2015 Dec 7. Oncogene. 2016. PMID: 26640149
-
Transgenic overexpression of a dominant negative mutant of FADD that, although counterselected during tumor progression, cooperates in L-myc-induced tumorigenesis.Int J Cancer. 2004 Nov 10;112(3):536-40. doi: 10.1002/ijc.20422. Int J Cancer. 2004. PMID: 15382083
-
Apoptosis and carcinogenesis.Br Med Bull. 1997;53(3):554-69. doi: 10.1093/oxfordjournals.bmb.a011630. Br Med Bull. 1997. PMID: 9374037 Review.
-
The great MYC escape in tumorigenesis.Cancer Cell. 2005 Sep;8(3):177-8. doi: 10.1016/j.ccr.2005.08.005. Cancer Cell. 2005. PMID: 16169462 Review.
Cited by
-
The Role and Regulation of the NKG2D/NKG2D Ligand System in Cancer.Biology (Basel). 2023 Aug 2;12(8):1079. doi: 10.3390/biology12081079. Biology (Basel). 2023. PMID: 37626965 Free PMC article. Review.
-
Spotlight on New Therapeutic Opportunities for MYC-Driven Cancers.Onco Targets Ther. 2023 Jun 7;16:371-383. doi: 10.2147/OTT.S366627. eCollection 2023. Onco Targets Ther. 2023. PMID: 37309471 Free PMC article. Review.
-
Lessons from Using Genetically Engineered Mouse Models of MYC-Induced Lymphoma.Cells. 2022 Dec 22;12(1):37. doi: 10.3390/cells12010037. Cells. 2022. PMID: 36611833 Free PMC article. Review.
-
Targeting the MYC interaction network in B-cell lymphoma via histone deacetylase 6 inhibition.Oncogene. 2022 Sep;41(40):4560-4572. doi: 10.1038/s41388-022-02450-3. Epub 2022 Sep 6. Oncogene. 2022. PMID: 36068335 Free PMC article.
-
PI(18:1/18:1) is a SCD1-derived lipokine that limits stress signaling.Nat Commun. 2022 May 27;13(1):2982. doi: 10.1038/s41467-022-30374-9. Nat Commun. 2022. PMID: 35624087 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous